Cambridge and Saffron Walden, UK, 21st April 2023 / Sciad Newswire / Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period. This growth was achieved organically, coincided with the challenging backdrop of the COVID-19 pandemic and is a testament to the company’s excellent reputation and commitment to delivering high-…
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
● Vad Lazari Ph.D., appointed to newly created position of VP of Biology, based in Stevenage, UK
● Joins from Charles River and brings two decades of drug discovery experience including at Pfizer and BioFocus DPI
● Will be responsible for leading the biology to support NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatments for Parkinson's and…
Funding targets a critical unmet clinical need to treat autoimmunity, which affects around 300 million people globally
Awarded as part of £25 million Innovate UK Biomedical Catalyst fund
Cambridge, UK – 19 April 2023 – Biotechnology company Maxion Therapeutics (‘Maxion’) today announced it has been awarded a prestigious GBP £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody® platform to develop antibodies to treat autoimmune diseases (AID)…
- Sharpest rise in CFO optimism since 2020;
- Survey shows biggest decline on record for CFOs’ perceptions of external uncertainty;
- Brexit and energy risks ease;
- CFOs see artificial intelligence driving investment and productivity, but are divided on impact on jobs within the workforce.
Sentiment among finance leaders of the UK’s largest firms has improved significantly since the start of the year, according to Deloitte’s UK CFO Survey Q1 2023.
A net 25%1 of CFOs are more optimistic about the financial prospects of their business than they were three months ago. Having run well below the…
20th March 2023 Nijmegen, The Netherlands and Biocity Nottingham UK
Alveron Pharma announces that it has commenced a Phase 1 clinical study for OKL-1111, a new drug for the treatment of Intracranial Haemorrhage (ICH) and other life-threatening bleeds associated with the use of anticoagulants or platelet inhibitors. The clinical trial is taking place in the UK and will investigate safety, pharmacokinetics and pharmacodynamics in man.
ICH is a devastating condition with a 30-50% mortality rate and is also responsible for approximately 50% of disability associated with stroke…
Do you have a winning commercialisation strategy?
If you are a startup that:
- Is developing therapeutic innovations
- Has obtained a first proof-of-concept OR a £1-3m funding
- Has integrated digital technologies (ML/AI) in the R&D workflow OR is planning to
Apply to SBC Catalyser programme!
You'll end the free 8-week programme with:
- A refined commercialisation strategy to go from prototype to commercially-viable product
- A better understanding of how to improve / embed digital technologies (ML/AI) to accelerate your R&D
- Access to SBC extensive network of experts, mentors…
CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines.
The facility will act as the new research & development (R&D) site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.
Babraham Research Campus is an internationally recognized life sciences cluster, with over 60 companies and 2,000 employees co-located with the Babraham Institute providing shared facilities and supporting programs. The Campus is one of…
The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation.
Now available with the option of simple to use control myoblasts, stem cell researchers looking to differentiate stem cells to skeletal muscle with multinucleated myotubes can produce consistent, high-quality results every time. Methods for studying muscular disease and potential therapies were, until recently, dependent on invasive muscle biopsies to produce limited batches of…
April’s eNews is here to continue the #lifesciences conversation on:✅ Upcoming Events✅ Storytelling in Corporate Communication✅ Our Collaboration with United Airlines✅ Meet our Ecosystem in our Annual Review✅ ON Helix✅ Cambridge Facilities and Lab SpaceRead it here
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER
- Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A
- Will play a key role in building and executing Arecor’s ambitious commercialisation and growth plans as pipeline of proprietary and partnered products advances
Cambridge, UK, 5 April 2023: Arecor…